ramosetron Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting. Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women". In India it is marketed under the brand name of Ibset.   Wikipedia

Chemistry

  • SMILES: Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21
  • InChIKey: NTHPAPBPFQJABD-LLVKDONJSA-N
  • Mol. Mass: 279.34
  • ALogP: 2.89
  • ChEMBL Molecules:
    ramosetron  
    ramosetron hydrochloride  
More Chemistry

Pharmacology

Alternative names

5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1h-benzimidazol | ibsetron | ibsetron hcl | ibsetron hydrochloride | irribow | methanone, (1-methyl-1h-indol-3-yl)(4,5,6,7-tetrahydro-1h-benzimidazol-5-yl)-, monohydrochloride, (r)- | nasea | ramosetron | ramosetron hcl | ramosetron hydrochloride | ym060 | ym 060 | ym-060

Organizations (25)

Research & Development (25)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (2)


 

Nausea

Vomiting

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Ambulatory Surgical Procedures (Phase 4)

Breast Neoplasms (Phase 4)

Colostomy (Early Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Drugs, Investigational (Phase 1)

Fecal Incontinence (Phase 2/Phase 3)

Fractures, Bone (Phase 4)

Healthy Volunteers (Phase 1)

Heart (Phase 4)

Hematologic Neoplasms (Phase 2)

Irritable Bowel Syndrome (Phase 4)

Nausea (Phase 4)

Neoplasms (Phase 4)

Osteoarthritis, Knee (Phase 4)

Ovarian Neoplasms (Phase 3)

Postoperative Nausea and Vomiting (Phase 4)

Stomach Neoplasms (Phase 3)

Vomiting (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 53
  • # of Trial Organizations: 25

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue